Status:

TERMINATED

A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF

Lead Sponsor:

PETHEMA Foundation

Conditions:

Diabetic Patients With Critic Ischemia in Lower Limbs Who Are Administered With CD133+ Cells Mobilized by G-CSF

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

The primary objective is to analyze the safety and efficacy of CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs. The secondary ob...

Detailed Description

A total of up to 20 diabetic patients with critic ischemia of lower limbs will be included in the study. Patients will be administered with CD133+ cells, that previously have been obtained of their pe...

Eligibility Criteria

Inclusion

  • According to the investigator opinion, patient is able to carry out with all the clinical trial requirements
  • Patient must volunteer sign the inform consent before any study specific test, that is not part of the common patient attention, is performed. Patient must know that he/she can abandon the study at any time with no damage to his/her posterior attention
  • Age 18 to 75
  • A diagnosis of chronic critic ischemia of the lower limbs
  • Diabetes Mellitus active
  • III or IV stages (Fontaine classification): resting pain, ulcer or minor gangrene with no major amputation
  • General contraindication or local inoperability or refractory/progression after previous surgical treatment, according to the investigator criteria
  • If female reproductive potential, negative pregnancy test

Exclusion

  • Pregnant or currently breast feeding women
  • Acute myocardial infarction within the last 3 years
  • Non re-vascular unstable angina pectoris
  • History of ischemia stroke within the last 3 years
  • Neoplasia at the time of inclusion or Chemotherapy or Radiotherapy treatment in the last 5 years
  • Chronic renal insufficiency
  • G-CSF contraindication
  • A non well controlled serious concomitant disease
  • History of serious thrombotic episodes within the past 3 years
  • Patients who have received other investigational therapy within 30 days previous to the study inclusion
  • Patients currently in other clinical trial or receiving any other investigational agent

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00765050

Start Date

January 1 2009

End Date

October 1 2012

Last Update

April 7 2014

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Hospital Virgen de la Arrixaca

Murcia, Spain

2

Clínica Universitaria de Navarra

Pamplona, Spain

3

Hospital Clínico Universitario

Salamanca, Spain

4

Hospital Joan XIII de

Tarragona, Spain